Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Payables (2016 - 2025)

Historic Payables for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $1.6 million.

  • Ironwood Pharmaceuticals' Payables fell 5015.45% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 5015.45%. This contributed to the annual value of $2.1 million for FY2024, which is 7283.52% down from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Payables is $1.6 million, which was down 5015.45% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Payables registered a high of $7.8 million during Q4 2023, and its lowest value of $118000.0 during Q1 2023.
  • In the last 5 years, Ironwood Pharmaceuticals' Payables had a median value of $1.4 million in 2025 and averaged $2.3 million.
  • Its Payables has fluctuated over the past 5 years, first tumbled by 7900.61% in 2021, then surged by 517288.14% in 2024.
  • Ironwood Pharmaceuticals' Payables (Quarter) stood at $935000.0 in 2021, then crashed by 48.34% to $483000.0 in 2022, then soared by 1521.12% to $7.8 million in 2023, then tumbled by 72.84% to $2.1 million in 2024, then fell by 24.17% to $1.6 million in 2025.
  • Its Payables was $1.6 million in Q3 2025, compared to $1.4 million in Q2 2025 and $5.8 million in Q1 2025.